ArticleTherapeutic advances in medical oncology2019
TROP2 overexpression in colorectal liver oligometastases is associated with poor prognosis after liver resection.
Article in Therapeutic advances in medical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 9 citations in OpenAlex.
- Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.British journal of cancer · 2023Trial
- Preclinical Pharmacological Evaluation of Sacituzumab Govitecan (IMMU-132) in TROP2-Positive Colorectal Liver Metastasis Models.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Identification of biomarkers associated with diagnosis of gastroesophageal junction adenocarcinoma and their correlation with immune infiltration.Discover oncology · 2026Article
- High Trop-2 expression in pulmonary sarcomatoid carcinoma reveals antibody-drug conjugate targeting Trop-2 is a promising therapeutic approach.Journal of translational medicine · 2025Article
- Predicting extensive metastasis in postoperative oligometastatic colorectal cancer.International journal of colorectal disease · 2025Article
- The Impact of Trophoblast Cell-Surface Antigen 2 Expression on the Survival of Patients with Gastrointestinal Tumors: A Systematic Review.Journal of personalized medicine · 2023Review
- Oligometastases: Characterizing the Role of Epigenetic Regulation of Epithelial-Mesenchymal Transition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Review
- Structural insights into theiScience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to assess trophoblast antigen protein 2 (TROP2) expression in liver oligometastases and its prognostic value for colorectal liver oligometastasis (CLO) patients undergoing liver resection.
methodsWe retrospectively selected 129 consecutive CLO patients who underwent curative liver resection between June 1999 and December 2016. Immunohistochemistry (IHC) was performed to detect TROP2 expression in paraffin-embedded specimens. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method and log-rank test, and independent prognostic factors were identified with Cox regression modeling.
resultsTROP2 was expressed in 72.9% (94/129) of liver oligometastatic tissues. TROP2 expression in primary tumors and liver oligometastases was significantly positively correlated (
conclusionsTROP2 overexpression was associated with an unfavorable oncologic prognosis in patients with CLO undergoing liver resection. Detecting TROP2 expression may be valuable for guiding postoperative treatment among CLO patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.